Novo Nordisk sues Eli Lilly over allegedly misleading GLP-1 drug ads

• Novo Nordisk filed a federal lawsuit in New Jersey accusing Eli Lilly of false advertising in US consumer campaigns for Zepbound and Mounjaro.
• Complaint targets comparisons using Lilly’s highest doses against lower doses of Wegovy and Ozempic, omitting newer, more effective options.
• Novo argues ads exclude Wegovy 7.2 mg, cleared by the FDA in March 2026, which showed 18.8% average weight loss in a 72-week trial.
• Suit seeks a permanent injunction to pull the comparative ads across platforms, backed by a corrective advertising campaign.
• Novo signaled it may seek a preliminary injunction in the coming days to immediately block the advertising.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210735OMX_____CNEWS_EN_GNW1001213727_en) on July 21, 2026, and is solely responsible for the information contained therein.